Pioglitazone as Add-on THERAPY in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial

Ji Hye Heo,Kyung Ah Han,Jun Hwa Hong,Hyun-Ae Seo,Eun-Gyoung Hong,Jae Myung Yu,Hye Seung Jung,Bong-Soo Cha

DOI: https://doi.org/10.4093/dmj.2023.0314

2024-02-05

Diabetes & Metabolism Journal

Abstract:1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea 3 Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea 5 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea 6 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea 7 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea 8 Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Copyright © 2024 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Download PDF CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. AUTHOR CONTRIBUTIONS Conception or design: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y., H.S.J., B.S.C. Acquisition, analysis, or interpretation of data: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y., B.S.C. Drafting the work or revising: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y. Final approval of the manuscript: J.H.H., K.A.H., J.H.H., H. A.S., E.G.H., J.M.Y., H.S.J., B.S.C. FUNDING This study was sponsored by Jeil Pharmaceutical Co. Ltd., Seoul, South Korea. The sponsor participated in the study design, data management, and analysis. Values are presented as mean±standard deviation or number (%). BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell function; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OHA, oral hypoglycemic agent. Values are presented as mean±standard deviation unless otherwise indicated. HbA1c, glycosylated hemoglobin; LS, least square; SE, standard error; CI, confidence interval; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Values are presented as number (%). P <0.05 denotes statistical significance. TEAE, treatment-emergent adverse event; ADR, adverse drug reaction; AE, adverse event; NA, not available.

endocrinology & metabolism